Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (65051)	8/13/2021 11:15:23 AM
From: Doug R	Respond to of 79450

EVOK 8dRSI signal history and current trigger line:

To: Doug R who wrote (65051)	8/13/2021 2:35:00 PM
From: Trumptown	Read Replies (2) \| Respond to of 79450

The difference a penny makes... ;~) What's Up With Evoke Pharma's Stock Popping Off Friday? 12:02 pm ET August 13, 2021 (Benzinga) Print Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 cents per share which beat the analyst consensus estimate of a loss of 8 cents per share. “Through our continuing commercial expansion, increasing in-person access to physicians, and growing visibility within the gastroparesis community, we are encouraged by the momentum achieved in the second quarter,”stated David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “Notably, we continued to observe positive trends in refill rates, sales growth, and prescribing physicians, affirming our belief that we are gaining traction among new doctors and patients. As we enter the second half of the year, we look forward to driving our commercial and marketing initiatives forward and establishing GIMOTI as the preferred treatment option for patients suffering from diabetic gastroparesis,” Gonyer said. Evoke Pharma is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Evoke Pharma has a 52-week high of $5.87 and a 52-week low of $1.04.